ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AbbVie Inc (ABBV) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company demonstrates strong revenue growth and maintains its Dividend King status, the technical indicators, options sentiment, and recent financial performance suggest a cautious approach. The lack of significant positive trading signals and mixed analyst sentiment further support a hold recommendation.
The MACD histogram is negative (-1.65) and contracting, RSI is neutral at 45.588, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 213.772, with key support at 203.527 and resistance at 224.017. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
AbbVie has maintained its Dividend King status, increasing dividends for 54 consecutive years, appealing to income-focused investors.
Strong performance of new drugs Skyrizi and Rinvoq, which have driven significant revenue growth.
Analysts from RBC, Barclays, and Piper Sandler have issued optimistic price targets, citing growth potential and operating leverage.
Concerns over competition in the immunology space and the impact of Humira's patent expiration.
Mixed analyst sentiment, with some firms lowering price targets and expressing concerns about long-term growth.
Recent financials show a sharp decline in net income (-5743.75% YoY) and EPS (-5200.00% YoY), despite revenue growth.
In Q4 2025, AbbVie reported a 10.04% YoY increase in revenue to $16.62 billion. However, net income dropped significantly by -5743.75% YoY to $1.81 billion, and EPS declined by -5200.00% YoY to 1.02. Gross margin improved slightly to 72.61%, up 2.43% YoY. The financial performance reflects strong revenue growth but significant challenges in profitability.
Recent analyst ratings are mixed. RBC, Barclays, and Piper Sandler are optimistic with price targets of $260, $275, and $299, respectively, citing growth potential and operating leverage. However, UBS, Evercore ISI, and Citi have lowered their price targets, expressing concerns about long-term growth and competitive dynamics. Wolfe Research downgraded the stock to Peer Perform, reflecting a cautious stance.
